Profile: Bioanalytical Systems Inc (BASI.O)

BASI.O on Consolidated Issue listed on NASDAQ Capital Market

2.52USD
23 Sep 2014
Price Change (% chg)

$0.12 (+4.94%)
Prev Close
$2.40
Open
$2.45
Day's High
$2.52
Day's Low
$2.45
Volume
17,197
Avg. Vol
11,172
52-wk High
$3.80
52-wk Low
$1.25

Search Stocks

Bioanalytical Systems, Inc., incorporated on July 17, 1975, is an international contract research organization providing drug discovery and development services and analytical instruments. The Company's clients and partners include pharmaceutical, biotechnology, academic and government organizations. The Company derives its revenues from sales of its research services and drug development tools. The Company supports the preclinical and clinical development needs of researchers and clinicians for small molecule and biomolecule drug candidates.

The Company's principal clients are scientists engaged in analytical chemistry, drug safety evaluation, clinical trials, drug metabolism studies, pharmacokinetics and basic research from small start-up biotechnology companies to many of the global pharmaceutical companies. The Company operates in two business segments: contract research services and research products, both of which addresses the bioanalytical, preclinical, and clinical research needs of drug developers.

Services

The contract research services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance and quality control testing. Analytical methods, primarily performed in West Lafayette, Indiana, determine potency, purity, chemical composition, structure and physical properties of a compound. Methods are validated to ensure that data generated are accurate, precise, reproducible and reliable and are used consistently throughout the drug development process and in later product support. The Company analyzes specimens from preclinical and clinical trials to measures drug and metabolite concentrations in complex biological matrices. Bioanalysis is performed at the Company's facilities in West Lafayette, Indiana.

The Company tests stability of drug substances and formulated drug products and maintain secure storage facilities in West Lafayette, Indiana to establish and confirm product purity, potency and shelf life. The Company has multiple International Conference on Harmonization validated controlled-climate GMP (Good Manufacturing Practices) systems in place, and the testing capability to complete stability programs.

The Company provides preclinical in vivo sampling services for the continuous monitoring of chemical changes in life, in particular, how a drug enters, travels through, and is metabolized in living systems. Those services are performed in customized facilities in West Lafayette and Evansville, Indiana using the Company's robotic Culex APS (Automated Pharmacology System). The Company provides pharmacokinetic and safety testing in studies ranging from acute safety monitoring of drugs and medical devices to chronic, multi-year oncogenicity studies in its Evansville, Indiana site.

Research Products

The Company focuses its products business on expediting preclinical screening of developmental drugs. The Company competes in small niches of the multibillion dollar analytical instrument industry. The products business targets niches in life science research. The Company designs , develop, manufacture and markets vivo sampling systems and accessories, including disposables, training and systems qualification.

The Company offers three principal product lines: Analytical Products, In vivo Sampling Products and Vetronics’ Products. The analytical products consist of the Company's liquid chromatographic and electrochemical instruments with associated accessories. The in vivo sampling products consist of the Culex family of automated in vivo sampling and dosing instruments. These are used by pharmaceutical researchers to dose animals and collect biological samples (blood, bile, urine, microdialysate, feces or any bio-fluid) from the animals. Since dosing and sample collections are automated, animals are not manually handled, reducing stress on the animals and producing more representative pharmacological data. Behavior and other physiological parameters can also be monitored simultaneously. The line also includes in vivo sampling devices sold to drug developers and medical research centers to assist in the study of a number of medical conditions including stroke, depression, Alzheimer’s and Parkinson’s diseases, diabetes and osteoporosis. The Vetronics’ products consist of instruments and related software to monitor and diagnose cardiac function (electro-cardiogram) and measure other vital physiological parameters primarily in cats and dogs in veterinary clinics.

The Company competes with Covance, Inc.; Pharmaceutical Product Development, Inc.; Charles River Laboratories, Inc., and Quintiles Transnational Holdings, Inc.

Company Address

Bioanalytical Systems Inc

2701 Kent Avenue, Purdue Researc
WEST LAFAYETTE   IN   47906
P: +1765.4634527
F: +1765.4971102

Search Stocks